Genmab A/S (NASDAQ:GMAB) Price Target Raised to $41.00 at HC Wainwright

Genmab A/S (NASDAQ:GMAB) had its target price increased by HC Wainwright from $40.00 to $41.00 in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other analysts have also recently issued reports about the company. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research note on Thursday. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Finally, Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and an average target price of $39.75.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $29.06 on Monday. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $33.65. The stock has a market capitalization of $18.66 billion, a price-to-earnings ratio of 12.37, a PEG ratio of 1.56 and a beta of 0.96. The firm has a fifty day moving average of $29.69 and a two-hundred day moving average of $24.55.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a return on equity of 24.48% and a net margin of 41.36%.The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently modified their holdings of GMAB. Orbis Allan Gray Ltd grew its holdings in shares of Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after buying an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after acquiring an additional 2,084,966 shares during the last quarter. First Trust Advisors LP grew its stake in shares of Genmab A/S by 3.5% during the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock worth $36,575,000 after acquiring an additional 60,504 shares in the last quarter. Brandywine Global Investment Management LLC raised its holdings in shares of Genmab A/S by 1.6% in the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock valued at $36,047,000 after purchasing an additional 27,372 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Genmab A/S by 112.4% in the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after purchasing an additional 665,893 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.